Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Author(s)
Cummins, K; Gill, S;
Journal Title
Hematology/Oncology Clinics of North America
Publication Type
Review
Abstract
Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 have emerged as the most common targets for CAR T cells in AML. CAR T cells against myeloid antigens cause myeloablation as well as cytokine release syndrome, although neurotoxicity is rarely seen. Future efforts should focus on AML-specific antigen discovery or engineering, and on further enhancing the activity of CAR T cells.
Publisher
Elsevier
Keywords
Acute myeloid leukemia; CAR T cells; Crs; Cellular immunotherapy; Myeloablation
Department(s)
Clinical Haematology
PubMed ID
37442676
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-10-17 06:55:51
Last Modified: 2024-07-09 05:19:56

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙